Providing seizure freedom for patients with focal refractory epilepsy

EpilepsyGTx is a late preclinical-stage biotech developing cutting-edge gene therapies that will transform the management of focal refractory epilepsy (FRE).

Our goal is to make patients with FRE seizure free.

For further information please contact us.

Our mission

Our mission is to make patients with focal refractory epilepsy seizure-free

Our people

Our team provides a unique combination of worldwide leading expertise in epilepsy research and in the development and commercialisation of gene therapy

Meet us

Our approach

Our scientific strategy revolves around the targeted delivery of gene therapy to the seizure focus

Learn more

News

July 2026

EpilepsyGTx appoints Dr Teresa Nunes as Chief Medical Officer

• Appointment of senior clinical leader will support progression of lead candidate EPY201 through the clinic … London, UK…

July 2026

EpilepsyGTx partners with ClearPoint Neuro to support targeted delivery of lead gene therapy in epilepsy

• ClearPoint Neuro’s system enables precise delivery to the seizure focus, ensuring best possible efficacy and safety of…

April 2026

EpilepsyGTx appoints Professor Dimitri Kullmann as Chief Scientific Officer

• Appointment of UCL Neurologist will accelerate the delivery of novel gene therapies for refractory epilepsy … London, UK…

December 2025

EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy

• Investment from XGEN Venture, British Business Bank, and a global biopharmaceutical company will support first-in-human…